论文部分内容阅读
目的探讨CDX2和前列腺特异性抗原(PSA)联合检测在前列腺癌和结直肠癌鉴别诊断中的价值。方法应用免疫组化方法检测57例前列腺癌、20例良性前列腺组织和40例结直肠腺癌中CDX2和PSA的表达。结果10.5%(6/57)的前列腺癌中可见CDX2的表达,CDX2的表达与前列腺癌的Gleason分级无相关性(P>0.05)。50%的前列腺导管腺癌弥漫强阳性表达CDX2,所有结直肠腺癌均弥漫性强阳性表达CDX2。PSA在所有前列腺癌中表达,但不表达于结直肠腺癌中。结论CDX2可表达于前列腺癌中,特别是前列腺导管腺癌,CDX2和PSA联合检测可有助于前列腺癌和转移性结直肠癌的鉴别。
Objective To explore the value of combined detection of CDX2 and prostate specific antigen (PSA) in the differential diagnosis of prostate cancer and colorectal cancer. Methods The expressions of CDX2 and PSA in 57 cases of prostate cancer, 20 cases of benign prostatic tissue and 40 cases of colorectal adenocarcinoma were detected by immunohistochemistry. Results The expression of CDX2 was found in 10.5% (6/57) of prostate cancer. There was no correlation between the expression of CDX2 and the Gleason grade of prostate cancer (P> 0.05). Fifty percent of prostatic ductal adenocarcinomas are diffusely strongly positive for CDX2, and all of the colorectal adenocarcinomas are diffusely strongly positive for CDX2. PSA is expressed in all prostate cancers, but not in colorectal adenocarcinomas. Conclusion CDX2 can be expressed in prostate cancer, especially in prostate adenocarcinoma. Combined detection of CDX2 and PSA may be helpful for the differential diagnosis of prostate cancer and metastatic colorectal cancer.